Gamma heavy chain disease treated with daratumumab-based regimen: a first case report and review of literature.

IF 2.3 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2025-08-01 Epub Date: 2025-08-21 DOI:10.1080/1750743X.2025.2549673

Carla Cicerchia, Tristan Vaugeois, Nathalie Forgeard, Jean-François Alexandra, Floriane Theves, Stéphanie Harel, Bruno Royer, Sophie Rousselet, Antoine Diep, Patricia Palmic, Bertrand Arnulf, Alexis Talbot

引用次数: 0

Abstract

We report on the use of a daratumumab-CHOP regimen for treatment of gamma heavy chain disease (γHCD) in a 79-year-old woman. γHCD is a very rare hematological disease, often associated with an underlying lymphoproliferative disorder. Only a few cases are reported in the literature, and, therefore, strong evidence is lacking regarding new therapeutic strategies. We attempted a treatment with a monoclonal anti-CD38 antibody in association with conventional chemothorapy, due to CD38 expression by clonal cells. This is the first reported case in the literature, in a disease in which very few novel strategies have recently emerged.

查看原文本刊更多论文

以达拉图单抗为基础的方案治疗γ重链疾病：首例病例报告和文献综述

我们报道了一名79岁女性使用daratumumab-CHOP方案治疗γ重链病（γHCD）。γ - hcd是一种非常罕见的血液病，通常与潜在的淋巴细胞增生性疾病相关。文献中仅报道了少数病例，因此，缺乏关于新的治疗策略的有力证据。由于克隆细胞表达CD38，我们尝试用单克隆抗CD38抗体联合常规化疗进行治疗。这是文献中首次报道的病例，在这种疾病中，最近很少有新的策略出现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.